Roche announced its MabThera cancer drug can be combined with chemotherapy to extend the lives of patients with indolent non-Hodgkin's Lymphoma. New data revealed by the Swiss firm indicated Rituxan, marketed in the U.S. by Roche's Genentech unit and Biogen Idec, prolonged lives for at least two years after treatment.

Full Story:

Related Summaries